CMPS COMPASS Pathways Plc American Depository Shares Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
19:30
Aug 25
Aug 25
Author is bullish on psychedelics and explicitly hopes CMPS catches up.
Author is bullish on psychedelics and explicitly hopes CMPS catches up, implying a forward-looking long view while PSIL is context.
12:52
Aug 17
Aug 17
Reports most closed positions across funds
"Reports most closed positions across specialist funds in Q2 2026 excluding M&A take-outs, no directional view."
MED
12:50
Aug 17
Aug 17
Reports most reduced positions across funds
"Reports most reduced positions across specialist funds in Q2 2026 excluding M&A take-outs, no directional view."
MED
11:53
Aug 17
Aug 17
Reports most reduced positions by specialist funds
Reports the most reduced positions by specialist funds in Q2 2026, excluding M&A takeouts.
MED
11:27
Aug 15
Aug 15
The author compiles a thread of user-recommended non-AI tickers as a research watchlist.
The author compiles a thread of user-recommended non-AI tickers as a research watchlist, explicitly noting he cannot guarantee they are all non-AI, so these are indexed as watch rather than trade ideas.
LOW
17:11
Aug 10
Aug 10
The author defends their binary event call accuracy by listing past winners and losers.
The author defends their binary event call accuracy by listing past winners and losers, but frames it as a track record defense rather than a current position or forward call.
LOW
14:00
Jul 23
Jul 23
Psychedelic stocks poised for asymmetric gains.
The psychedelic drug sector is an asymmetric upside opportunity. It is underfollowed, clinical trial data is positive, regulatory tailwinds are emerging (RFK Jr., FDA fast-tracking), and big pharma validation arrived with Eli Lilly's acquisition of Atai. Stocks like Compass Pathways, Definium/MindMed, and the PSI ETF stand to benefit significantly.
HIGH
17:38
Jul 16
Jul 16
Buy CMPS as a cheaper, more clinically advanced alternative to LLY and ATAI.
Buy CMPS as a cheaper, more clinically advanced alternative to LLY and ATAI in the psychedelic/mental health space, with notable institutional fund interest per the parent thread context endorsed by the author.
MED
13:50
Jul 05
Jul 05
Author notes CMPS is up ~100%+ YTD and states 'It’s still a sector I like over the long run' with a belief in enormous addressable market for psychedelic therapies.
Author notes CMPS is up ~100%+ YTD and states 'It’s still a sector I like over the long run' with a belief in enormous addressable market for psychedelic therapies.
Risk: Regulatory setbacks or slower-than-expected adoption could reverse gains; valuation may be stretched after large run-up.
13:23
Jun 22
Jun 22
CMPS is a psychedelic stock named as a watch idea alongside DFTX, benefiting from the same sector tailwinds and potential for regulatory catalysts.
MED
21:19
Jun 09
Jun 09
Buy CMPS on the catalyst that psilocybin microdoses may treat obesity, fatty liver.
Buy CMPS on the catalyst that psilocybin microdoses may treat obesity, fatty liver, and diabetes — a significant new indication that could dramatically expand the addressable market if regulatory/pharma opposition doesn't block development.
MED
21:57
Jun 08
Jun 08
Author endorses psychedelic stocks as a good sector to be long with massive upside potential.
Author endorses psychedelic stocks as a good sector to be long with massive upside potential, but does not state a personal position in the specific tickers.
05:55
Jun 05
Jun 05
Author discloses ongoing long position
Author discloses an ongoing long position in the stock.
MED
08:21
May 18
May 18
Compass Pathways is developing psychedelic therapy for treatment-resistant depression. Commenter (MD/PhD) claims it may lead a paradigm shift. Small-cap biotech with a novel, high-potential pipeline; if FDA approval path clears, significant upside. A speculative early-stage biotech bet on a new treatment class; high risk/reward. Regulatory rejection, clinical trial failures, competitive landscape (e.g., MAPS), capital dilution.
LOW
05:43
Apr 19
Apr 19
Compass Pathways (CMPS) is listed as one of the author's holdings poised to benefit from accelerated psychedelic therapy approvals. The author's logic is that sector-wide positive news will lift all boats in the psychedelic biotech space. A generic long bet on the sector, tied to a vague political headline. CMPS has its own clinical trial risks. The post's catalyst is not specific to CMPS. Stock performance may not correlate with political news.
MED
18:29
Mar 15
Mar 15
The author provides a routine portfolio update detailing additions, reductions.
The author provides a routine portfolio update detailing additions, reductions, and closures across various biotech stocks.
12:07
Feb 24
Feb 24
Highlights strong past biotech performance
Author highlights strong past performance of several asymmetric biotech bets made earlier in the year.
LOW
10:58
Jun 23
Jun 23
CMPS Phase 3 lacks commercial conviction
Notes Phase 3 results are regulatory sufficient but lack commercial conviction to justify high price expectations, advising to wait for 26-week data.
MED
19:10
May 19
May 19
Active long with asymmetric upside potential.
Author discloses an active long position, highlighting a highly favorable asymmetric risk/reward profile with significant upside potential.
MED
08:31
Mar 02
Mar 02
Promising data drives likely FDA approvals
Author bought QURE and is bullish on this basket of biotech names, citing very promising clinical data and a high likelihood of FDA approvals within the next 1-2 years.
MED
About CMPS Analyst Coverage
Buzzberg tracks CMPS (COMPASS Pathways Plc American Depository Shares) across 8 sources. 5 bullish vs 0 bearish calls from 8 analysts. Sentiment: predominantly bullish (25%). 20 total trade ideas tracked. Latest voices: incomesharks, seedy19tron, thebigberbowski.